NIZBRO 100 CAPSULE

ACEBROPHYLLINE HAS 3 ACTIONS NAMELY BRONCHODILATION, MUCOREGULATION & ANTI-INFLAMMATORY ACTION.

PHARMACOLOGY

A.)PHARMACODYNAMICS: Acebrophylline inhibits intracellular phosphodiesterase associated significantly reduce airway inflammation and obstruction in chronic stages. Acebrophylline increases the synthesis and release of alveolar surfactant, resulting in triple action: mucoregulation, stimulation of bronchoalveolar clearance, and anti-inflammatory-interactive effect. In patients with chronic obstructive bronchitis, given the drug for 10-20 days, there was a good reduction in expectorate Viscosity. with cAMP levels and facilitates bronchial muscles relaxation. Acebrophylline selectively inhibits phosphatidylcholine and phospholipase A, TNF-alpha, and leukotrienes. Inhibition of such pro-inflammatory mediators can.

B.)PHARMACOKINETICS:

• Absorption: – 200mg oral acebrophylline, the two components of the molecule ambroxol and theophylline-7-acetic acid are released in the stomach and absorbed in the intestine, reaching optimal concentrations of ambroxol within 2hrs and of theophylline-7-acetic acid after 1 hr.

• Half-Life: – The plasma half-life varies from 4 to 9 hrs after oral administration.

• Metabolism: – The drug is metabolized in the liver and eliminated really.

Indications: Treatment of adult patients with COPD and bronchial asthma.